[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gerd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gerd":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,43,75,103,134,156,176,205,233,258,277,303,324,347,371,392,417,447,458,481,501,527,549,569,590],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053546","the-effect-of-the-reflux-band-upper-esophageal-sphincter-ues-assist-device-on-reflux-for-lung-transplant-recipients-100053546",false,"NCT03886961","The Effect of the Reflux Band™ Upper Esophageal Sphincter (UES) Assist Device on Reflux for Lung Transplant Recipients","Reflux Band","Inclusion Criteria:\n\n* Clinically stable lung transplant patients(single lung, double lung, or re-transplant) as defined by stable FEV1 over the prior two visits\n* 13 Abnormal pH impedence or esophagram or documented gastric reflux at pre-transplant evaluation\n* Patient must be willing and able to provide informed consent\n* Understands the clinical study requirements and is able to comply with follow-up schedule\n\nExclusion Criteria:\n\n* Currently being treated with another investigational medical device and\u002For drug\n* Currently receiving treatment for sleep apnea with continuous positive airway pressure (CPAP)\n* Previous head or neck surgery \u002F radiation\n* Carotid artery disease, thyroid disease, or history of cerebral vascular disease\n* Nasopharyngeal cancer\n* Suspected esophageal cancer","ALL","18 Years","80 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","A prospective, open label, study designed to assess the affect of the Reflux Band® UES Assist Device (Reflux Band) on reflux in patients that have undergone lung transplantation.",[28,29],"Lung Transplant","GERD","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2019-05-17",{"date":38,"type":22},"2027-12-20",{"name":40,"class":41},"University of Florida","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100641615","antireflux-surgery-without-preoperative-esophageal-manometry-100641615","NCT07659080","Antireflux Surgery Without Preoperative Esophageal Manometry","Laparoscopic Toupet Fundoplication With or Without Preoperative Esophageal Manometry in Patients With GERD and Hiatal Hernia","NOMA","Inclusion Criteria\n\n1. Age ≥ 18 years\n2. Documented GERD and\u002For hiatal hernia (Type I, II, or small Type III) confirmed on EGD and\u002For imaging (i.e. CT scan or upper GI study) within 12 months\n3. Presence of at least one guideline-based indication for antireflux surgery:\n\n   1. Typical GERD symptoms (heartburn and\u002For regurgitation) refractory to or recurrent after adequate PPI therapy\n   2. PPI-dependent GERD with patient preference for surgical management\n   3. Extra-esophageal GERD symptoms (chronic cough, laryngitis, asthma) with pathologic reflux confirmed on ambulatory pH study\n   4. Symptomatic Type II\u002FIII paraesophageal hernia (postprandial pain, early satiety, dysphagia to solids)\n   5. Objective documentation of pathologic esophageal acid exposure on ambulatory reflux monitoring (24-hour pH-impedance or 48-hour Bravo pH capsule) confirming GERD diagnosis, performed within 12 months of enrollment\n4. Mellow-Pinkas dysphagia score = 0 at baseline (no overt dysphagia)\n5. Eckardt score \\\u003C 1 (achalasia screening)\n6. Ability to provide informed consent and comply with 12-month follow-up.\n\nExclusion Criteria:\n\n1. Overt dysphagia (Mellow-Pinkas ≥ 1 or Eckardt ≥ 1)\n2. Prior esophageal or gastric surgery\n3. Known or clinically suspected achalasia or primary motility disorder\n4. Endoscopic stricture, mass, or luminal obstruction\n5. Giant paraesophageal hernia (Type IV, or Type III with \\>50% of stomach herniated intrathoracically)\n6. Connective tissue disease with esophageal involvement (e.g., scleroderma\u002FCREST)\n7. Active esophageal or gastric malignancy\n8. Pregnancy\n9. BMI \\> 40 kg\u002Fm² (patients with severe obesity who would be candidates for bariatric surgery should be referred for metabolic\u002Fbariatric evaluation, as per the multi-society GERD guideline recommending weight-loss surgery consideration in this population)\n10. Participation in another interventional trial within 30 days\n11. Prior esophageal manometry within 12 months demonstrating a major motility disorder (achalasia, absent contractility, distal esophageal spasm, hypercontractile esophagus); such patients should be managed per standard motility disorder pathways and are not candidates for this trial.",{"count":52,"type":22},96,[25],"The goal of this clinical trial is to learn if people can safely skip a test called esophageal manometry before surgery for acid reflux (gastroesophageal reflux disease, or GERD) or a hiatal hernia. Manometry measures the muscles of the food pipe using a thin tube passed through the nose. The test can be uncomfortable and can delay surgery. The main questions this study aims to answer are whether people can skip manometry and still have good swallowing one year after surgery, and whether skipping the test lowers discomfort, shortens the wait for surgery, and lowers cost. To answer this, researchers will compare two groups. One group will have surgery without manometry. The other group will have manometry first, the way it is usually done. Everyone will get the same operation, a partial wrap called a Toupet fundoplication, so the study tests the value of the test and not the surgery. Participants will be placed by chance into one of the two groups, have the same standard operation, and fill out short questionnaires about their swallowing before surgery and again at 3, 6, and 12 months after surgery. Researchers want to find out if skipping manometry works just as well as the usual approach for people who do not have trouble swallowing before surgery.",[29,56,57,58,59],"Hiatal Hernia","Heartburn","Paraesophageal Hernia","Gastroesophageal Reflux",[29,61,62,63,58],"hiatal hernia","fundoplication","Gastroesophageal Reflux Disease","NOT_YET_RECRUITING","2026-06-16",{"date":67,"type":34},"2026-06-22",{"date":69,"type":22},"2026-10-01",{"date":71,"type":22},"2028-04-30",{"name":73,"class":41},"McMaster University",2,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":42},"100475355","phase-1-a-study-to-investigate-the-pharmacokinetics-and-ecg-effects-of-linaprazan-glurate-100475355","NCT05469854","A Study to Investigate the Pharmacokinetics and ECG Effects of Linaprazan Glurate","A Phase I Trial to Investigate the Pharmacokinetics and ECG Effects of Single Doses of Linaprazan Glurate Administered as Oral Tablets to Healthy Participants","Main inclusion Criteria:\n\n1. Willing and able to give written informed consent for participation in the study.\n2. Healthy male or female aged 18 to 65 years\n3. Body mass index ≥18.5 and ≤35.0 kg\u002Fm2.\n4. Prospective subjects, as well as their partners, must agree to contraception requirements\n\nMain exclusion criteria:\n\n1. Female subjects of childbearing potential unless they agree to use highly effective methods of contraception (failure rate of \\\u003C1%) from 2 weeks prior to dosing until the end-of-study visit.\n2. Male subjects with a partner of childbearing potential, unless they agree to use method of contraception from 2 weeks prior to dosing until the end-of-study visit.History of or current clinically significant disease as defined in the protocol\n3. History of or current clinically significant disease as defined in the protocol.\n4. History of GERD, significant acid reflux.\n5. Subjects who are pregnant, currently breastfeeding, or intend to become pregnant (female subjects) or father a child (male subjects) during the course of the study (i.e., from screening to end of study visit).",true,"65 Years",{"count":85,"type":22},121,[87],"PHASE1","This is a Phase I, single-center, double blind, placebo-controlled, parallel-group, randomized trial designed to evaluate the PK, cardiodynamic ECG effects, safety, and tolerability of single oral doses of linaprazan glurate. The trial will explore the PK properties of linaprazan glurate and linaprazan as well as the cardiodynamic ECG effects, safety, and tolerability after the administration of single doses: 300 mg and 600 mg in Part I of the trial, using formulation A of linaprazan glurate, as well as 150 mg, 275 mg, and up to 2 additional dose levels, using formulation C of linaprazan glurate to reach target linaprazan mean Cmax exposure (5222 nmol\u002FL).",[90,91,92,29],"Pharmacokinetics","Cardiodynamic ECG","Safety, and Tolerability","2026-06-15",{"date":95,"type":34},"2026-06-17",{"date":97,"type":34},"2022-07-13",{"date":99,"type":22},"2026-11-30",{"name":101,"class":102},"Cinclus Pharma Holding AB","INDUSTRY",{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":42},"100534619","phase-4-famotidine-and-antacids-for-treatment-of-dyspepsia-100534619","NCT06241183","Famotidine and Antacids for Treatment of Dyspepsia","Comparing Intravenous Famotidine and Oral Antacids in the Treatment of Dyspepsia in the Emergency Department","Inclusion Criteria:\n\n1. Subject Age ≥ 18 years of age\n2. Patient diagnosed with dyspepsia\n3. Present at the ED with upper abdominal pain score of at least 3\n\nExclusion Criteria:\n\n1. Hypersensitivity to an ingredient in Maalox\u002F Mylanta or Famotidine\n2. Moderate to Severe Renal Insufficiency (precaution)\n3. Kidney Failure\n4. Pregnant or Nursing\n5. Verbal pain score less than 3\n6. Inability to tolerate oral medications\n7. Bowel Obstruction\n8. Proton pump inhibitor within 2 hours of study treatment",{"count":111,"type":22},80,[113],"PHASE4","The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox\u002F Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.",[116,29,117],"Dyspepsia","Acid Reflux",[119,29,117,120,121,122,123,124],"dyspepsia","H2 receptor antagonist","antacid","Maalox","Mylanta","Famotidine","2026-06-01",{"date":127,"type":34},"2026-06-02",{"date":129,"type":34},"2023-11-09",{"date":131,"type":22},"2027-12-31",{"name":133,"class":41},"Stony Brook University",{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":141,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":42},"100635715","phase-2-transoral-incisional-fundoplication-tif-for-patients-suffering-from-gastroesophageal-reflux-disease-in-an-asian-population-100635715","NCT07556289","Transoral Incisional Fundoplication (TIF) for Patients Suffering From Gastroesophageal Reflux Disease in an Asian Population","Inclusion Criteria:\n\n* 18 years - 80 years of age\n* More than 6 months of GERD symptoms and troublesome regurgitation, despite a minimum PPI dose of 40 mg daily. Troublesome regurgitation was defined as mild symptoms for 2 or more days per week or moderate to severe symptoms more than 1 day per week, per Montreal consensus criteria. Patients will be followed-up for 5 years.\n* Symptom assessment used the following 3 validated tools: the Reflux Disease Questionnaire (RDQ), and the GERD-QOL score on PPI and off PPI for at least 7 days.\n* Abnormal amounts of gastroesophageal reflux off PPI for 7 days was confirmed by distal esophageal pH \\\u003C4 for \\>5.3% of at least 1 of the 2 days that pH was measured with a Bravo (radiotelemetry) probe (Given Imaging, Yoqneam, Israel).\n\nExclusion Criteria:\n\n* Systemic disease not well controlled\n* Obesity determined by body mass index \\>35\n* Esophageal ulcer, stricture\n* Barrett's esophagus \\>2 cm in length\n* Hiatal hernia \\>2 cm in length\n* Los Angeles grade C or D esophagitis\n* Peptic ulcer disease\n* Gastroparesis\n* Pregnancy or plans for pregnancy in the next 12 months\n* Immunosuppression\n* Portal hypertension\n* Coagulopathy",{"count":21,"type":22},[142],"PHASE2","Transoral incisionless fundoplication (TIF) has become a widely used intervention to restore the valve at the gastroesophageal junction in selected patients suffering from gastroesophageal reflux disease (GERD). More than 20,000 procedures have been performed worldwide. TIF with EsophyX device reconfigures the tissue to establish an omega-shaped full-thickness gastroesophageal valve from inside the stomach. The procedure creates serosa to serosa plications which include the muscle layers and constructs valves 3-5cm long, taking in 200-270 degrees of the circumference, and deploying multiple non-absorbable polypropylene fasteners through the two layers in a circumferential patten around the gastroesophageal junction. Data so far indicate that, in the majority of patients, the procedure achieves lasting improvement in GERD symptoms measured by either pH or impedance monitoring. The technique offers an acceptable alternative to surgery, mimicking partial fundoplication, but less invasive and with no persistent side effects, in patients with proven pathological GERD with either a competent gastroesophageal valve or hiatal hernia, not longer than 3cm, who refuse, are intolerance, or are unresponsive to PPI maintenance therapy. Laparoscopic fundoplication, although still considered to be the gold-standard approach for GERD refractory to medical treatment, does involve some risk of long-term adverse events such as dysphagia (5-12%), inability to vomit or belch, gas\u002Fbloat syndrome (19%) and excessive flatulence.\n\nSeveral prospective observational studies and some comparative trials have proved efficacy of TIF with EsophyX in obtaining a significant reduction in the acid exposure time (AET) assessed by esophageal 24-hour pH-impedance monitoring versus sham, and in controlling both typical and atypical GERD symptoms for up to 1 to 2 years, as reported in a meta-analysis7. Outcomes at 3, 5, and 10 years have been reported in different studies and showed to be favourable. In an Italian study reporting the 10 year follow-up, the GERD-HRQL score, heartburn and regurgitation score were significantly lower than pre-procedure and did not change significantly during the follow-up. The rates of patients who had stopped or halved anti-secretive therapy 2, 3, 5, 7 and 10 years after the procedure were 86.7%, 84.4%, 73.5%, 83.3% and 91.7% respectively.\n\nThis procedure, however, has not been performed in Asia patients. Asians have smaller body build and is known to have less GERD when compared to the Caucasian population. This study, therefore, is a feasibility study to perform TIF in an Asian population.\n\nIn patients who fulfil the inclusion criteria, TIF will be performe under general anaesthesia. They will then be followed-up at 4 weeks, 3 months, then yearly for up to 5 years after the procedure. The anti-reflux control and adverse events will be recorded.",[145,29],"Fundoplication",[145,29],"2026-04-22",{"date":149,"type":34},"2026-04-29",{"date":151,"type":34},"2021-08-01",{"date":153,"type":22},"2026-08-01",{"name":155,"class":41},"Chinese University of Hong Kong",{"id":157,"slug":158,"hasResults":12,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":42},"100589523","vonaprazan-versus-esomeprazole-for-healing-of-la-grade-b-or-higher-esophagitis-after-poem-100589523","NCT06955520","Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM","Inclusion Criteria:\n\n* Age ≥18 years\n* History of POEM for achalasia\n* Endoscopic confirmation of LA grade B, C, or D reflux esophagitis at 3 months post-POEM\n* GERD symptoms (heartburn, regurgitation) for ≥4 weeks\n* Willingness to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* History of prior anti-reflux surgery\n* Presence of Barrett's esophagus, esophageal stricture, or malignancy\n* Severe gastroparesis or esophageal motility disorder unrelated to achalasia\n* Pregnancy or breastfeeding\n* Severe hepatic or renal impairment (ALT\u002FAST \\>3× ULN, eGFR \\\u003C30 mL\u002Fmin)\n* Regular use of NSAIDs, steroids, or anticoagulants affecting esophageal healing","75 Years",{"count":164,"type":22},300,[25],"Peroral Endoscopic Myotomy (POEM) is a well-established treatment for achalasia; however, it is frequently associated with gastroesophageal reflux disease (GERD), with many patients developing LA grade B or higher esophagitis. Proton pump inhibitors (PPIs) like Esomeprazole are the standard treatment, but Vonaprazan, a potassium-competitive acid blocker (P-CAB), offers superior acid suppression and may provide enhanced healing in post-POEM reflux esophagitis.\n\nPrimary Objective:\n\n• To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks in patients receiving Vonaprazan 20 mg versus Esomeprazole 40 mg.\n\nSecondary Objectives\n\n* To assess improvement in reflux symptoms using the GERD-Q score at 8 weeks.\n* To evaluate the incidence of adverse events in each treatment group.",[29],{"date":169,"type":34},"2026-04-27",{"date":171,"type":34},"2025-04-30",{"date":173,"type":22},"2028-12-25",{"name":175,"class":41},"Asian Institute of Gastroenterology, India",{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":29,"eligibilityCriteria":182,"healthyVolunteers":12,"sex":17,"minAge":183,"maxAge":19,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":42},"100634803","diaphragmatic-training-on-gerd-100634803","NCT07544433","Diaphragmatic Training on GERD","Diaphragmatic Training for Gastroesophageal Reflux Disease: A Randomized Controlled Trial Comparing the Effects of Diaphragmatic Breathing Exercise and Incentive Spirometry Training on Esophageal Dynamics and Quality of Life","Include Criteria:\n\n* Age between 20 and 80 years.2. A confirmed diagnosis of gastroesophageal reflux disease (GERD), defined by at least one of the following criteria\n* Endoscopic examination within the past 3 months demonstrating Los Angeles (LA) grade A reflux esophagitis with regular use of acid-suppressive medication (e.g., proton pump inhibitors) for more than 2 months.\n* 24-hour esophageal pH monitoring showing acid exposure time (AET) \\> 6%.\n* Endoscopic examination within the past 3 months demonstrating LA grade B or higher reflux esophagitis.\n* Willingness and ability to participate in the intervention program, including adherence to training protocols, scheduled follow-up visits, and completion of all required assessments during the study period.\n\nExclusion Criteria\n\n* Pregnant or breastfeeding women.\n* History of anti-reflux surgery or other upper gastrointestinal surgical procedures related to GERD.\n* Presence of significant cardiopulmonary disease or chronic respiratory disease that may compromise the safety or feasibility of performing breathing training.\n* Inability to comply with the study protocol, including participation in training procedures and scheduled follow-up visits, due to conditions such as cognitive impairment, physical limitations, or inability to attend regular visits.","20 Years",{"count":185,"type":22},42,[25],"he goal of this clinical trial is to evaluate the effects of diaphragm-oriented breathing training on patients with gastroesophageal reflux disease (GERD). This study will compare two non-invasive respiratory interventions-diaphragmatic breathing exercise (DBE) and volume-oriented incentive spirometry (VIS)-in terms of their impact on esophageal function and health-related quality of life.The main questions it aims to answer are:Does DBE or VIS improve GERD symptoms as measured by the GERD Questionnaire (GERDQ)?Do these interventions reduce esophageal acid exposure time and the number of reflux episodes?Do these interventions improve lower esophageal sphincter (LES) pressure and esophageal motility?Do these interventions improve GERD-related quality of life as measured by the GERD-HRQL questionnaire?Researchers will compare three groups: DBE, VIS, and a control group receiving standard care, to determine whether diaphragm-oriented breathing training provides additional benefits over usual management.Participants will:Be randomly assigned to one of three groups (DBE, VIS, or control)Perform the assigned intervention for 6 weeksUndergo baseline and post-intervention assessments, including symptom questionnaires and esophageal function testing Record symptoms and adherence in a daily diary",[29,189],"Diaphragmatic Training",[29,191,192,193,194,195,196],"incentive spirometry","esophageal dynamics","quality of life","Diaphragmatic training","diaphragmatic breathing exercise","incentive spirometry training","2026-04-15",{"date":147,"type":34},{"date":200,"type":34},"2026-03-04",{"date":202,"type":22},"2028-09-30",{"name":204,"class":41},"Changhua Christian Hospital",{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":212,"targetDuration":214,"studyType":215,"phases":4,"briefSummary":216,"conditions":217,"keywords":222,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":42},"100631904","prospective-registry-of-esophageal-motility-100631904","NCT07506746","PRospective Registry of Esophageal Motility","PREM","Inclusion Criteria:\n\n1. Participant is willing and able to give informed consent for participation in the study.\n2. The procedures are the standard of care for the patient or the participant is taking the medicinal product according to clinical practice\n3. Aged \\> 18 years.\n4. Any typical (heartburn or regurgitation) or atypical reflux symptom (Laryngeal Cough, laryngitis, sub-glottic stenosis, globus, laryngeal cancer, vocal cord granuloma, vocal cord irritation, vocal cord polyps and post-nasal drip; Oropharyngeal: Dental erosion, pharyngitis, sore or burning throat, gingivitis and halitosis; Ears and sinuses: Earaches, otitis media and sinusitis; Pulmonary: Chronic bronchitis, pneumonia, aspiration, bronchiectasis, asthma and idiopathic pulmonary fibrosis; Cardiac: Arrhythmia, angina and myocardial infarction; Sleep: Sleep apnoea, sleep deprivation, insomnia, snoring, nightmare and sleep disturbance), but also any obstructive esophageal symptom potentially reflecting a primary or secondary motility disorder (oropharyngeal or esophageal dysphagia, chest pain, bolus impaction). Every patient with a diagnosis of esophageal inflammatory disorder (including EoE and others) or systemic rheumatological condition (scleroderma, systemic sclerosis, lichen planus and others), every patient previously undergone to any anti-reflux surgery, bariatric surgery, endoscopic or surgical esophageal or gastric myotomy (also for gastroparesis) may be included.\n5. Patients must be referred to the Digestive Physiopathology Unit of IRCCS San Raffaele Hospital for motility tests\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Not willing to provide informed consent to the inclusion in the registry",{"count":213,"type":22},10000,"10 Years","OBSERVATIONAL","Digestive physiopathology is a branch of gastroenterology aiming to study patients with upper GI symptoms, mainly gastro-esophageal, potentially indicating the presence of Gastroesophageal Reflux Disease (GERD)\u002FBarrett Esophagus (BE) or obstructive esophageal motility disorders (achalasia being the most relevant), but including also other primary motility disorders such as Esophgago-Gastric Junction Outflow Obstruction (EGJOO), Hypercontractile Esophagus (HE), Distal Esophageal Spasm (DES) and other minor disorders. Physiopathological testing encompasses High-Resolution Manometry (HRM), 24-H esophageal pH-impedance testing, Functional Lumen Imaging Probe (FLIP) assessment. All these tests are designed to provide a clear phenotyping of esophago-gastric disorders related to reflux or obstructive esophageal symptoms, either in naïve patients, as well as after foregut surgery (particularly anti-reflux surgery, achalasia\u002Fprimary motility disorders treatment).",[218,219,220,221,29],"Esophageal Diseases","Achalasia","Eosinophilic Esophagitis","Motility Disorder",[223],"Esophageal disease; manometry; FLIP, pH-impedance","2026-03-28",{"date":226,"type":34},"2026-04-02",{"date":228,"type":34},"2026-03-09",{"date":230,"type":22},"2041-03",{"name":232,"class":41},"IRCCS San Raffaele",{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":237,"acronym":4,"eligibilityCriteria":238,"healthyVolunteers":12,"sex":17,"minAge":239,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":23,"phases":242,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":42},"100416202","compassionate-use-of-domperidone-for-refractory-gastroparesis-100416202","NCT04699591","Compassionate Use of Domperidone for Refractory Gastroparesis","Inclusion Criteria:\n\n1. Male or female\n2. Age 12 - 21\n3. Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe dyspepsia or severe chronic constipation that are refractory to standard therapy.\n4. Patients must have a comprehensive evaluation to eliminate other causes of their symptoms.\n5. Patient has signed informed consent for the administration of domperidone that informs the patient of potential adverse events including:\n\n   * increased prolactin levels\n   * extrapyramidal side effects\n   * breast changes\n   * Cardiac arrhythmias including QT prolongation\n   * There is a potential for increased risk of adverse events with the drugs and herbal supplements listed in the addendum (See Addendum on pages 24 and 25)\n   * The coordinator\u002Finvestigator will have a discussion with the family about the use of any of the medications and herbal supplements listed in the addendum to make sure they understand the increased risk of their use and the need to contact the investigators prior to using any of the listed medications and herbal supplements.\n\nExclusion Criteria:\n\n1. History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.\n2. Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged Tc (QTc\\> 450 milliseconds for males, QTc\\>470 milliseconds for females).\n3. Clinically significant electrolyte disorders.\n4. Gastrointestinal hemorrhage or obstruction\n5. Presence of a prolactinoma (prolactin-releasing pituitary tumor).\n6. Pregnant or breast feeding female\n7. Known allergy to domperidone","12 Years","21 Years",{"count":21,"type":22},[25],"The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.",[29,59,245],"Gastroparesis",[247,248],"reflux","acid reflux","2026-03-20",{"date":251,"type":34},"2026-03-24",{"date":253,"type":4},"2013-04",{"date":255,"type":22},"2035-12",{"name":257,"class":41},"Jose Cocjin",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":162,"enrollmentInfo":265,"targetDuration":4,"studyType":23,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":42},"100589405","a-randomized-three-arm-study-comparing-vonaprazan-10-mg-vonaprazan-20-mg-and-esomeprazole-40-mg-for-the-healing-of-la-grade-b-or-higher-reflux-esophagitis-at-8-weeks-100589405","NCT06953986","A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks","Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks","Inclusion Criteria:\n\n* Adults ≥18 years of age.\n* Endoscopically confirmed LA grade B, C, or D reflux esophagitis.\n* GERD symptoms (heartburn, regurgitation) for at least 4 weeks prior to enrollment.\n* Willing to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Previous or ongoing treatment with Vonaprazan or Esomeprazole in the last 4 weeks.\n* Prior esophageal surgery or radiation therapy.\n* Barrett's esophagus, esophageal stricture, or malignancy.\n* Pregnant or breastfeeding women.\n* History of PPI-refractory GERD or severe gastroparesis.\n* Significant hepatic or renal impairment (ALT\u002FAST \\>3× ULN, eGFR \\\u003C30 mL\u002Fmin).\n* Use of NSAIDs, steroids, or anticoagulants affecting healing.",{"count":266,"type":22},414,[25],"Primary Objective\n\n• To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks among patients treated with Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg once daily.\n\nSecondary Objectives\n\n* To assess the improvement in reflux symptoms using the GERD-Q score at 8 weeks.\n* To evaluate the incidence of adverse events across treatment groups.",[29],{"date":271,"type":34},"2026-03-06",{"date":273,"type":34},"2025-12-20",{"date":275,"type":22},"2027-12-12",{"name":175,"class":41},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":284,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":295,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":42},"100625313","phase-1-pharmacokinetics-bioequivalence-and-safety-study-of-trimedat-7695-mg-orally-disintegrating-tablets-and-trimedat-100-mg-tablets-in-healthy-volunteers-100625313","NCT07421011","Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.","A Randomized, Open-label, Crossover Study to Assess the Comparative Pharmacokinetics, Bioequivalence, and Safety of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.","Inclusion Criteria:\n\n1. Voluntarily and personally signed informed consent form by a healthy volunteer obtained prior to the conduct of any study-related procedure;\n2. Males and females aged 18 to 45 years (inclusive) of Caucasian race.;\n3. Verified healthy status as demonstrated by the absence of clinically significant abnormalities in medical history, physical and instrumental examination, laboratory tests, and other diagnostic procedures specified in the protocol;\n4. Blood pressure (BP) level: systolic blood pressure (SBP) from 100 to 130 mm Hg (inclusive), diastolic blood pressure (DBP) from 70 to 89 mm Hg (inclusive);\n5. Heart rate (HR) from 60 to 89 beats per minute (inclusive);\n6. Respiratory rate (RR) from 12 to 20 breaths per minute (inclusive);\n7. Body temperature from 36.0°C to 36.9°C (inclusive);\n8. Body mass index (BMI) between 18.5 kg\u002Fm² and 30 kg\u002Fm², with a minimum body weight of ≥ 55 kg for men and ≥ 45 kg for women;\n9. Consent to use adequate contraceptive methods throughout the study and for 30 days after its completion, with a negative urine pregnancy test result for women of childbearing potential.\n\nNon-Inclusion Criteria:\n\n1. Clinically significant allergic history;\n2. Hypersensitivity to active and\u002For excipient substances in the investigational drug and comparator drug in the medical history;\n3. Drug intolerance to active and\u002For excipient substances in the investigational drug and comparator drug in the medical history;\n4. Known galactose intolerance, lactase deficiency, or glucose-galactose malabsorption;\n5. Chronic diseases of the kidneys, liver, gastrointestinal tract (GIT), cardiovascular, lymphatic, respiratory, nervous, endocrine, musculoskeletal, urogenital, and immune systems, as well as skin, hematopoietic organs, and the eye;\n6. Surgical interventions on the GIT in the medical history (except for appendectomy performed at least 1 year prior to screening);\n7. Diseases\u002Fconditions that, in the investigator's judgment, may affect the absorption, distribution, metabolism, or excretion of the investigational drugs;\n8. Acute infectious diseases less than 4 weeks before screening;\n9. Use of drugs that significantly affect hemodynamics and drugs affecting liver function (barbiturates, omeprazole, cimetidine, etc.) less than 2 months before screening;\n10. Regular use of medications less than 2 weeks before screening and single use of medications less than 7 days before screening (including over-the-counter drugs, vitamins, dietary supplements, herbal medicines);\n11. Blood or plasma donating within 3 months prior to screening;\n12. Use of hormonal contraceptives (in women) within 2 months prior to screening;\n13. Use of depot injections of any medications within 3 months prior to screening;\n14. Pregnancy or lactation; positive urine pregnancy test result for women of childbearing potential;\n15. Female subjects of childbearing potential who had unprotected sexual intercourse with an unsterilized male partner within 30 days prior to administration investigational drugs;\n16. Participation in another clinical study within 3 months prior to screening or concurrently with this study;\n17. Consumption of more than 10 alcohol units per week (1 unit of alcohol is equivalent to 500 ml of beer, 200 ml of wine, or 50 ml of strong alcoholic beverages) in the last month before inclusion in the study or a history of alcoholism, drug addiction, or substance abuse;\n18. Smoking more than 10 cigarettes per day currently or smoking that amount in the past 6 months prior to screening; unwillingness to refrain from smoking during hospitalization;\n19. Consumption of alcohol, caffeine, and xanthine-containing products within 7 days prior to taking investigational drugs;\n20. Consumption of citrus fruits, cranberries, rose hips and products containing them, or preparations\u002Fproducts containing St. John's wort within 7 days prior to taking investigational drugs;\n21. Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours prior to taking investigational drugs;\n22. Positive blood test for antibodies to human immunodeficiency virus (HIV) types 1 and 2, antibodies to Treponema pallidum antigens, hepatitis B surface antigen (HBsAg), antibodies to hepatitis C virus antigens during screening;\n23. ECG abnormalities in medical history and\u002For during screening;\n24. Positive urine test for narcotic substances and potent medications during screening;\n25. Positive breath alcohol test result during screening;\n26. Planning hospitalization during the study period for any reason other than hospitalization specified in the study protocol;\n27. Inability or unwillingness to comply with protocol requirements, perform procedures prescribed by the protocol, or adhere to dietary and activity restrictions;\n28. Membership in a vulnerable population, including but not limited to students of medical, pharmaceutical and dental educational institutions, junior staff of clinics and laboratories, employees of pharmaceutical companies, military personnel, prisoners, residents of care facillities, individuals with low income or unemployed, members of ethnic minorities, homeless persons, vagrants, refugees, individuals under guardianship or conservatorship, individuals unable to provide informed consent and law enforcement personnel;\n29. Other conditions that in the judgment of the Investigator may prevent volunteer inclusion in the study or lead to premature withdrawal from the study including adherence to fasting or special diets (e.g., vegetarianism, veganism, salt restriction) or special lifestyles (night work, extreme physical exertion).\n\nExclusion Criteria:\n\n1. Withdrawal of the volunteer from further participation in the study;\n2. Non-compliance by the volunteer with the study participation rules (missed study procedures, self-administration of drugs prohibited in the study, violation of dietary and lifestyle restrictions, etc.);\n3. Emergence of reasons\u002Fsituations during the study that threaten the safety of the volunteer (e.g., hypersensitivity reactions, etc.);\n4. Volunteers selected for participation in the study who do not meet inclusion\u002Fexclusion criteria;\n5. Development of a severe and\u002For serios adverse event (AE\u002FSAE) in the volunteer during the study;\n6. The volunteer undergoes or requires treatment that may affect the pharmacokinetic parameters (PKP) of the investigational drugs;\n7. Missed collection of 2 or more consecutive blood samples or 3 or more blood samples within one study period;\n8. Occurrence of vomiting\u002Fdiarrhea within 6 hours after taking the investigational drug;\n9. Positive urine test for narcotic substances and potent medications;\n10. Positive breath test for alcohol vapors;\n11. Positive pregnancy test result in women;\n12. Emergence of other circumstances during the study that preclude conducting the study according to the protocol.","45 Years",{"count":286,"type":22},36,[87],"This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat® 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat® 100 mg tablets in healthy volunteers under fasted conditions.",[290,291,29,292,293],"Irritable Bowel Syndrome","Gallstone Disease","Biliary Dyskinesia","Postcholecystectomy Syndrome","2026-02-11",{"date":296,"type":34},"2026-02-19",{"date":298,"type":34},"2025-11-06",{"date":300,"type":22},"2026-12-31",{"name":302,"class":102},"Valenta Pharm JSC",{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":310,"enrollmentInfo":311,"targetDuration":4,"studyType":23,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":42},"100492748","mechanisms-preventing-pharyngeal-reflux-100492748","NCT05696184","Mechanisms Preventing Pharyngeal Reflux","Pathophysiology of Pharyngo-esophageal Junction and Esophageal Mechanisms Preventing Pharyngeal Reflux of Gastric Content","Inclusion Criteria:\n\n* Age 18 to 85\n\n  * GERD patients with complaints of regurgitation and supra-esophageal symptoms will be included and recruited from our GI \\& Otolaryngology clinics\n  * GERD patients without complaint of supra-esophageal symptoms and regurgitation will be included and recruited from our GI \\& Otolaryngology clinics\n  * Asthma patients with and without supra-esophageal symptoms will be included and recruited from clinics affiliated with Medical College of Wisconsin. Asthma patients with the following classifications of asthma severity will be included: intermittent, mild persistent, moderate persistent, and severe persistent (as long as no acute asthma exacerbation at the time of the study)\n  * Patient definition will be based on position statement and technical reviews of the American Gastroenterological Association and Montreal definition and classification of gastroesophageal and reflux disease (Am J Gastroenterol. 2006;101:1900-1920).\n  * SERD is defined as patients on long term acid suppressive therapy complaining of persistent regurgitation along with supra-esophageal manifestations such as burning throat, asthma, chronic cough, or hoarseness. Patients will be screened by Reflux Symptom Index \\> 13.\n  * Barrett's esophagus patients will be recruited based on histological diagnosis from previous endoscopic biopsy that will be found using the clinical database warehouse.\n\nExclusion Criteria:\n\n* Age \\\u003C18 or \\>85\n\n  * Active alcohol or drug abuse\n  * History of ear, nose, throat and pulmonary diseases suspected of being GERD induced\n  * History of head and neck malignancy and chemo-radiation therapy to the head and neck\n  * Unable to give consent\n  * Pregnant women (see justification in the Women and Minority Inclusion in Clinical Research section)\n  * History of allergy to Lidocaine for nasal topical anesthesia\n  * Allergy to green food dye\n  * Asthma patients with an acute asthma exacerbation with symptoms including breathlessness, wheezing, and chest tightness","85 Years",{"count":164,"type":22},[25],"The overall goal is to define and characterize the manometric characteristics of UES incompetence associated with objectively documented pharyngeal reflux. The investigators will use endoscopic reflux detection as gold standard.",[29],"2026-02-06",{"date":317,"type":34},"2026-02-10",{"date":319,"type":34},"2013-11-01",{"date":321,"type":22},"2026-10-12",{"name":323,"class":41},"Medical College of Wisconsin",{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":29,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":17,"minAge":331,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":335,"conditions":336,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":337,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":346},"100613609","phase-4-heartburn-gastroesophageal-reflux-disease-100613609","NCT07268820","Heartburn, Gastroesophageal Reflux Disease","A Multicenter, Double-blind, Randomized, Investigator-initiated Trial to Evaluate the Degree of Symptom Relief of Zastaprazan and Esomeprazole in Patients With Erosive Reflux Disease With Night-time Heartburn Symptoms","Inclusion Criteria:\n\n1. Korean adults aged 19 years or older as of the date of written consent\n2. Those diagnosed with erosive gastroesophageal reflux disease based on upper gastrointestinal endoscopy (EGD)\n3. Those who reported nighttime heartburn for more than 3 months at the time of screening (Visit 1)\n4. Those who voluntarily decided to participate and provide written informed consent\n\nExclusion Criteria:\n\n1. Those who cannot undergo upper gastrointestinal endoscopy (EGD)\n2. Individuals with a history of drug or alcohol abuse (within the past year)\n3. Individuals who have received other investigational products within one month prior to the screening visit (Visit 1)\n4. In addition to the above, individuals with clinically significant findings that the investigator deems medically inappropriate for the present study","19 Years",{"count":333,"type":22},160,[113],"Gastroesophageal reflux disease (GERD) is a condition caused by the reflux of stomach contents into the esophagus, presenting with typical symptoms such as heartburn and acid regurgitation.\n\nGERD is a chronic condition that affects quality of life, and patients with this condition are known to have a lower quality of life compared to healthy individuals. In particular, nocturnal heartburn can lead to sleep deprivation and affect daily life, as well as overall quality of life.\n\nThis study aims to evaluate the efficacy of alleviating nocturnal heartburn symptoms in patients with erosive reflux disease (ERD).",[29],"2025-12-16",{"date":339,"type":34},"2025-12-23",{"date":341,"type":34},"2025-07-07",{"date":343,"type":22},"2026-09-30",{"name":345,"class":41},"Incheon St.Mary's Hospital",10,{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":356,"studyType":215,"phases":4,"briefSummary":357,"conditions":358,"keywords":360,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":42},"100610432","utility-of-mucosal-impedance-device-in-chronic-esophageal-disorders-100610432","NCT07227506","Utility of Mucosal Impedance Device in Chronic Esophageal Disorders:","Diagnostic Utility of Mucosal Impedance Device in Patients With GERD and Chronic Esophageal Disorders:","Inclusion Criteria:\n\n1\\. Patients with chronic esophageal symptoms such as atypical or typical reflux symptoms and dysphagia, is here for upper endoscopy testing.\n\nExclusion Criteria:\n\n1. Presence of esophageal stricture\n2. Unstable patients who cannot undergo this testing.\n3. Patients on anticoagulation on the day of procedure.\n4. Presence of esophageal cancer.\n5. Pregnancy.\n6. Minor patients.",{"count":355,"type":22},50,"1 Year","Background \\& Significance Chronic benign esophageal disorders such as Gastroesophageal reflux disease (GERD) and eosinophilic esophagitis are common gastrointestinal disorders affecting nearly 20% and 0.1% of the population, respectively. Although these conditions are frequent, the diagnosis of GERD or EoE requires complex decision making involving endoscopic examination, histopathological examination, and esophageal pH testing. This translates into significant economic burden; For example, burden due to GERD is about $24 billion annually. Additionally, there may be a delay in the diagnosis of GERD or EoE as Investigators might have to do multiple procedures such as upper endoscopy, esophageal pH testing, etc for the same participant for confirmation of the diagnosis. In addition, there could be overlay between GERD and EoE in the diagnosis which make cause delay in the diagnosis and decision making.\n\nAim:\n\nHere, Investigators will plan to identify the diagnostic utility and cost-effectiveness of this novel Mivu device(FDA approved) in the diagnosis of gastroesophageal reflux disease or chronic esophageal inflammatory disorders in participants with reflux symptoms or chronic esophageal symptoms.",[359,220],"Gerd",[361,362],"gerd","eosinophilic esophagitis","2025-11-11",{"date":365,"type":34},"2025-11-13",{"date":367,"type":22},"2025-11-20",{"date":369,"type":22},"2028-07-01",{"name":323,"class":41},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":42},"100514148","mesh-vs-pledgets-for-repair-of-paraesophageal-hernia-100514148","NCT05974722","Mesh Vs Pledgets for Repair of Paraesophageal Hernia","A Randomized, Blinded, Parallel-group Trial Evaluating Mesh Versus Pledgeted Sutures in Paraesophageal Hernia Recurrence","Inclusion Criteria:\n\n* 18 years of age or older\n* Willing and able to provide informed consent\n* Willing and able to participate in long-term follow up including study visits and surveys\n* Type II, III, or IV hiatal hernia \\> 5 cm, confirmed via upper GI studies, CT, or MRI 5 cm or greater hernia confirmed intraoperatively\n\nExclusion Criteria:\n\n* Pregnancy\n* BMI \\>45\n* Allergy to any components of mesh\n* Patients undergoing PEHR with a concurrent bariatric procedure or other procedure to reduce stomach volume (sleeve gastrectomy, roux-en-y gastric bypass, duodenal switch, single-anastomosis gastric bypass, and partial or total gastrectomy)\n* Patients who have undergone previous hiatal hernia repair",{"count":379,"type":22},164,[25],"The goal of this clinical trial is to compare whether the use of Ovitex mesh provides superior reduction in 2-year recurrence compared to pledgeted suture closure (no mesh) for patients undergoing paraesophageal hernia repair at the Cleveland Clinic. The main questions it aims to answer are:\n\n* Determine whether there is a difference in 2-year rates of radiographic recurrence with Ovitex versus pledgeted sutures in paraesophageal hernia repair.\n* Assess patient quality of life (QOL) after paraesophageal hernia repair with pledgets and mesh. A two-tailed research hypothesis will be used to determine whether there are differences between the two arms",[58,29],"2025-10-02",{"date":385,"type":34},"2025-10-07",{"date":387,"type":34},"2023-09-11",{"date":389,"type":22},"2028-12",{"name":391,"class":41},"David Krpata",{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":397,"acronym":4,"eligibilityCriteria":398,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":399,"enrollmentInfo":400,"targetDuration":4,"studyType":23,"phases":401,"briefSummary":402,"conditions":403,"keywords":404,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":42},"100525770","endoscopic-band-ligation-for-treating-reflux-disease-100525770","NCT06126055","Endoscopic Band Ligation for Treating Reflux Disease","EndoBand: Endoscopic Band Ligation for Treating Reflux Disease (GERD)","Inclusion Criteria:\n\n* Symptomatic GERD\n\nExclusion Criteria:\n\n* Any previous surgery for GERD","50 Years",{"count":346,"type":22},[25],"GERD is a chronic disease the require different treatment modalities; non have proven long term efficacy with concerns about their safety. The use of band ligation in endoscopy appears safe, repeatable with short learning curve. Placing multiple bands at the Z-line can create a fibrous ring in the distal esophagus acting as a barrier against reflux of gastric content.",[29],[29,405,406,407],"GastroEsophageal Reflux","Band Ligation","EndoBand","2025-08-05",{"date":410,"type":34},"2025-08-08",{"date":412,"type":22},"2025-12-01",{"date":414,"type":22},"2027-12-01",{"name":416,"class":41},"El Katib Hospital",{"id":418,"slug":419,"hasResults":12,"nctId":420,"briefTitle":421,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":425,"briefSummary":426,"conditions":427,"keywords":432,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":445,"locationsCount":42},"100382135","real-life-study-of-changes-of-gastroesophageal-reflux-disease-manifestations-due-to-behavioural-and-diet-adherence-100382135","NCT04255693","Real-life Study of Changes of Gastroesophageal Reflux Disease Manifestations Due to Behavioural and Diet Adherence","Inclusion Criteria:\n\n* willingness to participate (based on the signed informed consent form);\n* presence of gastroesophageal reflux disease, based on the following: a) typical symptoms, like heartburn and\u002For regurgitation (for primary selection, symptoms should be present at least weekly, be actual for at least 3 months prior to the enrolment, and the patient should report the history of symptoms which lasts for at least 6 months); b) previous response to the intake of proton pump inhibitors; c) data of 24-hours oesophageal pH-impedance monitoring with detected pathological gastroesophageal reflux according to the Lyon consensus definitions;\n\nExclusion Criteria:\n\n* pregnant or breast-feeding females;\n* abdominal or chest surgery (except appendectomy or cholecystectomy in case they are not followed by adhesive disease of the abdominal organs);\n* constant use of non-steroidal anti-inflammatory agents (NSAIDs), sporadic use of NSAIDs will be allowed in case the course of treatment was discontinued at least 2 weeks prior to the enrolment, in case that constant use of NSAIDs happen to be necessary after the enrolment, the patients may continue in the study but doses, frequency and duration of treatment should be carefully documented;\n* history or current evidence of cancer of any aetiology and location besides skin cancer in situ successfully treated before the enrolment;\n* severe patient's conditions which may lead to misinterpretation of data, or in case of patient's enrolment may put him at risk of exacerbation of co-morbid conditions, or in cases when on discretion of the investigator patient's condition would not allow him to complete the course of the observation. These conditions include, but not limited to: heart failure (class III-IV by NYHA), uncontrolled hypertension, severe neurological disorders, decompensated liver cirrhosis (Child-Pugh B or C), severe depression or other psychological disorders;\n* the patient may stop his participation in the study at any time by informing the site personal about his\u002Fher decision to withdraw the consent.",{"count":424,"type":22},150,[25],"This study is aimed to investigate the role of long-term diet adherence on manifestations of gastroesophageal reflux disease",[63,29,428,429,430,431],"Gastroesophageal Erosion","Erosive Esophagitis","Non-erosive Reflux Disease","Non-Erosive Gastro-Esophageal Reflux Disease",[29,433,434,435,436,437,438],"NERD","erosive esophagitis","diet","food","adherence","influence","2025-08-01",{"date":441,"type":34},"2025-08-03",{"date":443,"type":34},"2020-01-31",{"date":131,"type":22},{"name":446,"class":41},"Federal State Budgetary Scientific Institution \"Federal Research Centre of Nutrition, Biotechnology",{"id":448,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":449,"targetDuration":4,"studyType":23,"phases":450,"briefSummary":26,"conditions":451,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":452,"lastUpdatePostDateStruct":453,"startDateStruct":455,"completionDateStruct":456,"leadSponsor":457,"locationsCount":42},"100353828",{"count":21,"type":22},[25],[28,29],"2025-07-15",{"date":454,"type":34},"2025-07-16",{"date":36,"type":34},{"date":38,"type":22},{"name":40,"class":41},{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":464,"eligibilityCriteria":465,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":466,"targetDuration":4,"studyType":23,"phases":467,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":42},"100394925","functional-changes-in-the-stomach-and-esophagus-after-one-anastomosis-gastric-bypass--oagb-100394925","NCT04422405","Functional Changes in the Stomach and Esophagus After One Anastomosis Gastric Bypass- OAGB","Functional Changes in the Stomach and Esophagus After One Anastomosis Gastric Bypass- OAGB- BiFlux Trial","BiFLux","Inclusion Criteria:\n\n* BMI\\> 35 kg\u002Fm2\n* 2 years of controlled conservative obesity treatment without weight reduction\n* patients should give their consent to participate in the study\n\nExclusion Criteria:\n\n* Less than 2 years of conservative obesity treatment\n* cancer\n* cirrhosis Child-Pough score A\n* Crohn's disease\n* serious psychiatric disorder, which led to in-hospital treatment in psychiatric clinic in the past two years\n* drug consumption\n* non-compliance\n* hiatal hernia \\> 4cm\n* gastric pouch \\\u003C 10cm\n* Barett esophagus\n* erosive esophagitis Grade C or D according to the Los Angeles Classification\n* endoscopically proven gastric stricture\n* acid exposition time \\> 6% (Lyon criteria)\n* reflux episodes\\> 80 \u002F24 hours (Lyon criteria)\n* insufficient low esophageal sphincter according to manometry findings\n* pathological findings in the impedance pH-metry (acid and non-acid reflux)",{"count":164,"type":22},[25],"Evaluation of the functional changes in the stomach and esophagus of patients undergoing One Anastomosis Gastric Bypass (OAGB)",[470,29,471],"Obesity, Morbid","Ulcer, Gastric","2025-06-03",{"date":474,"type":34},"2025-06-06",{"date":476,"type":34},"2020-06-01",{"date":478,"type":22},"2035-05-28",{"name":480,"class":41},"Spital Limmattal Schlieren",{"id":482,"slug":483,"hasResults":12,"nctId":484,"briefTitle":485,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":23,"phases":489,"briefSummary":490,"conditions":491,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":497,"leadSponsor":499,"locationsCount":42},"100431693","truncal-vagotomy-in-patients-undergoing-revisional-sleeve-gastrectomy-to-gastric-bypass-100431693","NCT04901429","Truncal Vagotomy in Patients Undergoing Revisional Sleeve Gastrectomy to Gastric Bypass","Inclusion Criteria:\n\n* Participating subjects will need to be \\>18yrs of age and eligible for sleeve to bypass revision bariatric surgery.\n* Undergoing sleeve to bypass revision bariatric surgery.\n\nExclusion Criteria:\n\n* Patients who are under the age of 18.\n* Not eligible for sleeve to bypass revision bariatric surgery.",{"count":488,"type":22},200,[25],"The purpose of this study is to investigate the efficacy of performing a truncal vagotomy along with a sleeve to bypass revision surgery in reducing the severity and\u002For incidence of gastroesophageal reflux disease (GERD) post-surgery.",[29],"2025-05-21",{"date":494,"type":34},"2025-05-25",{"date":496,"type":34},"2021-07-01",{"date":498,"type":22},"2028-08-01",{"name":500,"class":41},"Baylor Research Institute",{"id":502,"slug":503,"hasResults":12,"nctId":504,"briefTitle":505,"officialTitle":506,"acronym":507,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":509,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":511,"conditions":512,"keywords":513,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":526},"100522588","prospective-evaluation-of-ph-impedance-tracings-according-to-the-wingate-consensus-and-influence-on-gerd-classification-according-to-the-lyon-consensus-100522588","NCT06084572","Prospective Evaluation of PH-impedance Tracings According to the Wingate Consensus, and Influence on GERD Classification According to the Lyon Consensus","Prospective Evaluation of PH-impedance Tracings According to the Wingate Consensus, and Influence on Gastro-oesophageal Reflux Disease (GERD) Classification According to the Lyon Consensus.","WinPro","Inclusion Criteria:\n\n* Adult patients aged 18 - 80 years old;\n* pH-MII performed off PPI\n\nExclusion Criteria:\n\n* Prior upper GI endoscopy indicative of structural disease (except for oesophagitis or hiatal hernia).\n* Incomplete pH-MII (less than 21 hours recording);\n* Ph-MII performed on PPI\n* Suboptimal quality of the tracings preventing interpretation in clinical practice;\n* Prior oesophageal (including anti-reflux intervention) or gastric surgery.",{"count":510,"type":22},120,"Commonly, in clinical practice an automated analysis of pH-MII tracings is obtained.",[29],[29,514,515,516],"pH-impedance","Wingate-consensus","Lyon consensus","2025-03-13",{"date":519,"type":34},"2025-03-19",{"date":521,"type":34},"2023-09-29",{"date":523,"type":22},"2026-04-01",{"name":525,"class":41},"Universitair Ziekenhuis Brussel",3,{"id":528,"slug":529,"hasResults":12,"nctId":530,"briefTitle":531,"officialTitle":532,"acronym":533,"eligibilityCriteria":534,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":535,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":538,"briefSummary":539,"conditions":540,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":42},"100565376","anti-reflux-endoscopic-therapy-using-argon-plasma-coagulation-area-in-gastroesophageal-reflux-disease-gerd-patients-a-single-center-randomized-sham-controlled-trial-the-area-study-100565376","NCT06641375","Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients: A Single Center, Randomized, Sham, Controlled Trial (The AREA Study)","Anti-Reflux Endoscopic Therapy Using Argon Plasma Coagulation (AREA) in Gastroesophageal Reflux Disease (GERD) Patients","AREA","Inclusion Criteria:\n\n* Patients with chronic GERD symptoms (at least 1 typical symptom of GERD, i.e. heartburn or acid reflux\u002Fregurgitation at least twice a week) for last 6 months and\n* Objective evidence of reflux disease (positive ambulatory pH study)\n* Patients prescribed standard dose of PPI for symptoms of GERD\n* Able to undergo upper endoscopy as evidenced by completion of pre-endoscopy standard of care checklist.\n\nExclusion Criteria:\n\n1. Patients unable to or unwilling to participate or consent\n2. Age \\\u003C18 years or \\>80 years\n3. Allergic or intolerant to PPI medications\n4. Large hiatal hernia \\> 3 cm and Hill grade IV\n5. Barrett's esophagus\n6. Esophageal stricture with any prior intervention\n7. Major motility disorder on HRM\n\n7\\. Eosinophilic esophagitis 8. Gastroparesis documented by abnormal gastric emptying time 9. Previous fundoplication, myotomy or LINX surgery 10. Cirrhosis with esophageal and\u002For gastric varices","70 Years",{"count":537,"type":22},18,[25],"Background and Rationale:\n\nGastroesophageal reflux disease is affecting 1 in 3 US adults with half experiencing daily symptoms. Per recent data, more than 50% continue to experience daily symptoms despite taking medical therapy and not eligible for surgery. In that small fraction of patients who are eligible for surgery, more than 70% resume taking a medicine for their reflux disease. GERD is common among the US veterans and currently there is a lack of minimally invasive endoscopic therapies for management of GERD. This study will investigate performance of minimally invasive, endoscopic therapy using antireflux mucosal ablation (hybrid argon plasma coagulation) that has been used in other areas of GI tract with efficacy and safety for management of chronic GERD among the US veterans.\n\nObjective:\n\nThe aim of this study is to assess the safety and effectiveness of antireflux mucosal ablation or ARAT (intervention group) in patients with chronic gastroesophageal reflux disease (GERD) symptoms (typical symptoms of GERD, i.e. heartburn or acid reflux\u002Fregurgitation at least twice a week) for the last 6 months and objective evidence of reflux disease (positive ambulatory pH study off PPI for 5-7 days) compared to sham procedure (control group).",[29],"2025-02-08",{"date":543,"type":34},"2025-02-12",{"date":545,"type":34},"2024-02-10",{"date":547,"type":22},"2025-12-10",{"name":175,"class":41},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":535,"enrollmentInfo":556,"targetDuration":4,"studyType":23,"phases":557,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":560,"lastUpdatePostDateStruct":561,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":42},"100499291","stretta-versus-conservative-treatment-100499291","NCT05781347","Stretta Versus Conservative Treatment","Endoscopic Treatment of Gastro-esophageal Reflux Disease with Application of Radiofrequency Energy to the Lower Esophageal Sphincter (Stretta) Versus Conservative Treatment, Prospective Randomized Study","Inclusion Criteria:\n\nVerified symptomatic GERD despite PPI use, with persistent symptoms, desire to discontinue PPIs, or intolerance to them.\n\nPathological gastroesophageal reflux confirmed by positive 24-hour pH-metry with impedance.\n\nNormal findings on high-resolution esophageal manometry (HRM) according to CCv4.0.\n\nAge ≥ 18 years. Signed informed consent for participation in the trial and invasive procedures.\n\nExclusion Criteria:\n\nActive severe reflux esophagitis (Los Angeles classification grade C or D). Barrett's esophagus. Esophageal peptic stricture or eosinophilic esophagitis. Hiatal hernia ≥ 2 cm. Malignancies. Abnormal findings on high-resolution esophageal manometry. Esophageal or subcardial varices. Pregnancy. Severe comorbidities or increased perioperative risk. Age \\> 70 years due to increased perioperative risk and common comorbidities. Symptoms primarily attributable to functional dyspepsia, significant anxiety, or depression, with overlap to other disorders of gut-brain interaction (DGBI).",{"count":355,"type":22},[25],"Gastroesophageal reflux disease (GERD) is one of the most common diseases of the gastrointestinal tract. Obesity is a significant risk factor for GERD; however, treatment outcomes in obese patients remain challenging. In the Czech Republic, therapeutic options are currently limited to conservative treatment, including pharmacotherapy and lifestyle modifications, or surgical interventions, both of which have known limitations. Stretta is a minimally invasive endoscopic therapy using radiofrequency energy delivered to the esophagogastric junction (EGJ) and cardia, aimed at enhancing the antireflux barrier.\n\nThis study evaluates the effectiveness and safety of the Stretta procedure compared to conservative treatment in managing GERD. Initially designed to compare outcomes between obese and non-obese populations, the study was expanded to include all GERD patients due to recruitment challenges and the need to meet strict eligibility criteria. These criteria ensure reliable results by focusing on patients with confirmed pathological GERD while excluding those with hiatal hernias ≥ 2 cm, severe esophagitis, or functional esophageal disorders such as hypersensitivity. The study aims to provide comprehensive data on the use of Stretta in the Czech Republic and its role in GERD management.",[29],"2025-01-05",{"date":562,"type":34},"2025-01-07",{"date":564,"type":34},"2022-09-01",{"date":566,"type":22},"2026-03-31",{"name":568,"class":41},"Military University Hospital, Prague",{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":573,"acronym":4,"eligibilityCriteria":574,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":575,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":577,"conditions":578,"keywords":579,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":581,"lastUpdatePostDateStruct":582,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":588,"locationsCount":42},"100551226","effect-of-helicobacter-pylori-eradication-on-gastroesophageal-refiux-disease-gerd-100551226","NCT06457334","Effect of Helicobacter Pylori Eradication on Gastroesophageal RefIux Disease (GERD)","Inclusion Criteria:\n\n* All patients diagnosed as GERD clinically and endscopically.\n\nExclusion Criteria:\n\n* NO exclusion criteria",{"count":576,"type":22},100,"Evaluate the effect of H.pylori eradication on Gastroesophageal-reflux disease and symptoms improvement",[29],[580],"Helicobacter pylori","2024-06-09",{"date":583,"type":34},"2024-06-13",{"date":585,"type":34},"2024-01-01",{"date":587,"type":22},"2025-01-01",{"name":589,"class":41},"Assiut University",{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":82,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":597,"targetDuration":4,"studyType":215,"phases":4,"briefSummary":599,"conditions":600,"keywords":603,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":610,"lastUpdatePostDateStruct":611,"startDateStruct":613,"completionDateStruct":615,"leadSponsor":617,"locationsCount":42},"100435061","9-step-magnetic-bariatric-revisional-surgery-100435061","NCT04945304","9-Step Magnetic Bariatric Revisional Surgery","9-Step Magnetic Assisted Conversion From Sleeve Gastrectomy to Roux-en-Y Gastric Bypass and Hiatoplasty by Single-Port.","Inclusion Criteria:\n\n* Older than 18 years\n* Candidate to bariatric surgery\n* Obesity\n* BMI Greater than 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Uncontrolled co-morbidities\n* patients with pacemakers, defibrillators, or other electromedical implants\n* Abnormal coagulation blood tests\n* Patients with hepatic diseases",{"count":598,"type":22},500,"RYGB represents one of the best alternatives for weight loss in obese patients achieving a weight loss of up to 60% and a resolution of comorbidities of 70%. Revision surgery contemplates multiple techniques including the conversion from one surgical technique to another, structural changes to the primary technique, among others. GERD is now a long-term problem for patients who have undergone LGS. RYGB is one of the best techniques to resolve this problem.",[601,29,602],"Bariatric Surgery Candidate","Revisional Bariatric Surgery",[604,605,606,607,608,609],"revisional surgery","bariatric surgery","gastric bypass","single port","sleeve gastrectomy","magnetic surgery","2022-07-07",{"date":612,"type":34},"2022-07-11",{"date":614,"type":34},"2021-05-31",{"date":616,"type":22},"2027-05-31",{"name":618,"class":41},"Unidad Internacional de Cirugia Bariatrica y Metabolica"]